Dried blood spot (DBS) technology has rapidly expanded beyond its original applications in neonatal screening. Today, it is becoming a valuable tool in toxicology, offering a minimally invasive, scalable, and cost-effective approach to sample collection and analysis. From therapeutic drug monitoring to substance abuse detection and environmental exposure studies, DBS is reshaping how toxicological testing is performed.
In this article, we examine the current scope of DBS in toxicology and explore the practical advantages and evolving use cases across clinical and forensic settings.
Conventional toxicology testing relies on venous blood collection, which requires trained personnel, cold-chain logistics, and immediate processing. The dried blood spot method, by contrast, involves collecting just a few drops of capillary blood from a finger prick onto a filter card, allowing the sample to dry and then be stored or shipped without refrigeration.
This shift provides several key benefits:
These advantages are driving broader adoption of DBS in toxicological workflows.
One of the most well-established uses of DBS in toxicology is therapeutic drug monitoring. DBS is particularly useful for:
Patients can collect samples at home and mail them to a lab, reducing hospital visits and enabling more frequent monitoring.
DBS is gaining traction in the detection of illicit drugs and banned substances. With sensitive analytical techniques such as LC-MS/MS, dried blood spots can be used to screen for:
In anti-doping efforts, DBS offers a discreet and easily transportable method for collecting blood samples from athletes, reducing logistical and privacy challenges compared to traditional phlebotomy.
DBS is also proving useful in biomonitoring efforts to assess exposure to toxic substances such as:
Population health studies increasingly use DBS to collect samples from large cohorts over time, especially in settings where traditional blood collection is not feasible. The long-term stability of DBS samples enables centralized analysis even months after collection.
Modern instrumentation has played a key role in making DBS viable for toxicology. Developments include:
These advancements help compensate for the smaller blood volume in DBS samples and support the expansion of multiplex testing panels.
Despite its promise, DBS has some limitations:
Nevertheless, ongoing research and standardization efforts are helping to overcome these barriers, making DBS more reliable and accepted for clinical and regulatory use.
At RDA Spot, we engineer our DBS kits and filter cards to meet the demanding requirements of toxicological analysis. Our materials are validated for drug stability and compatibility with advanced lab methods, helping our clients expand their testing capabilities with confidence.
Whether supporting hospital-based TDM programs or field-based exposure monitoring, our goal is to make toxicology testing more accessible, scalable, and accurate.
As toxicology evolves to meet the needs of decentralized healthcare, public health surveillance, and anti-doping enforcement, DBS stands out as a forward-looking solution. With proven applications and growing validation, the technology is poised to become a standard tool across multiple sectors.